Aurobindo Pharma

“We reiterate our FY guidance with the double-digit revenue growth, EBITDA margins north of 21% and absolute EBITDA in excess of 8,000 crore, with a potential upside from positive outperformance in our high-value strategic business areas.”

“We’ll be achieving the breakeven this quarter, Damayanti.”

“I think we can say, FY28 should be far better than FY27 because of the various initiatives and full year benefit of Lannett. Also, China will be moving up. And Biosimilar will also be there.”

“So, that means, we will be definitely sustaining this double-digit growth, at the same time, achieving further numbers.”

“And now we are back to full production capacities across plants. And so, like, I’m confident that whatever guidance we have given in the past, it is still on track.”

“No, that includes the strategic capital expenditure for the Biologics and also some of the product development, which are doing intangible asset for the partners’ products, global pharma major, all these things.”

“It’s very low because we have not started the MDI product manufacturing yet; we are still in the preparatory stage. And as far as the derma is concerned, we have just one product. It’s a smaller product. It does not have that kind of volume. We are looking for the future. I think in the next 6 months it will be better, 6 to 9 months. From there on I think the capacity will pick up.”

“The Lannett facility is underutilized. We had mentioned this when we bought it, it was underutilized. And one of our goals is also to utilize it to the extent we can and take the benefit out of it. These things take time.”

“Hopefully, probably in six months’ time, this will go aggressively. Because we have filed it, we are expecting some regulatory approvals and other things.”

“Formulation generated revenue of 9,102 crores, growing 24% year-on-year and accounting for approximately 89% of the consolidated revenue.”

“API revenue stood at 1,162 crores, growing 21% year-on-year and contributing approximately 11% of the overall revenue.”

“In the US, revenue was 4,555 crores, equivalent to USD 477 million, reflecting growth of 25% year-on-year.”

“Europe delivered revenue of €288 million, with constant currency growth of 18%.”

“Revenue from growth market is 1,026 crores or USD 107 million, representing year-on-year growth of 16%.”

“Yeah, I mean, broad number, it will be in billions. The market is in billions. So, what is our potential is on how much we are able to grab it. It is several billions, I would say.”

“But my understanding is that it may be around 20% possibly. That is one view. I don’t want to be overly optimistic, but somewhere around 20% is what my understanding is.”

“Loss of exclusivity over the next decade is a large opportunity for Biosimilars.”

“One is Lannett itself, they’re trying to integrate effectively and then improving the yields and the capacity utilization. Plus, other businesses like China will plan to start delivering in a big way. Plus, we are also having the biosimilars, biologics, etc., coming in the coming years.”

“Operating EBITDA was 2,156 crores, growing at 28% year-on-year with a margin of 21%, despite increase in input cost and freight rate.”

“Gross margin for the quarter was 61.2% compared to 59.7% in the corresponding period last year, while contribution stood at 6,280 crores.”

“R&D expenditure for the quarter stood at 376 crores against INR 344 crores in previous quarter.”

“So, we had an increase in the raw material procurement cost due to the Gulf issue, but still the overall impact of the cost has not gone into the consumption. It will be happening in the coming quarter also.”

“We have generated a very strong cash flow of USD 146 million during the quarter after funding strategic investments and capital allocation initiatives, and closed with a net cash position of USD 189 million.”

“Average finance cost of 4.9%, and profit after tax for the quarter was 1,124 crores.”

“During the quarter, we launched 10 products in the US, filed 7 ANDAs and received 12 final approvals.”

“We completed the acquisition of Lannett, further strengthening our US presence and expanding our capabilities in complex and controlled”

“The A1 Biochem acquisition makes an important step towards establishing an integrated, end-to-end small molecule CRDMO business, with capability spanning the value chain and experience of handling the development portfolio of more than 800 projects.”

“We launched ADQUEY, our first new chemical entity / NDA product for atopic dermatitis, alongside the launch of the dedicated dermatology business and unit focused on developing and commercializing high- value dermatology products.”

“The launch of key products such as generic Advair and the approval of generic QVAR marked the milestones in our expansion into the high-value respiratory segment, leveraging our capabilities in complex inhalation products.”

“There is no one-offs.”

“The Raleigh unit recently received a VAI classification, supporting the regulatory pathway for additional filings and approval in transdermal, dermal and respiratory products, and reinforcing our plans to expand in these differentiated segments.”

“Yes, we have filed the anti- dumping, and the notifications have been issued by the government.”

“We are pleased to report our highest ever revenue for the quarter of 10,263 crores, representing year-on-year growth of 24%.”

“So, Lanex is not part of Aurobindo. Lannett is part of Aurobindo, and Lannett is not marketing this, nor has plans to do it anytime soon.”